GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Debt-to-Revenue

InflaRx NV (InflaRx NV) Debt-to-Revenue : 152.75 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

InflaRx NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.41 Mil. InflaRx NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.81 Mil. InflaRx NV's annualized Revenue for the quarter that ended in Dec. 2023 was $0.01 Mil. InflaRx NV's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 152.75.


InflaRx NV Debt-to-Revenue Historical Data

The historical data trend for InflaRx NV's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Debt-to-Revenue Chart

InflaRx NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only N/A N/A N/A N/A 17.71

InflaRx NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A 4.62 152.75

Competitive Comparison of InflaRx NV's Debt-to-Revenue

For the Biotechnology subindustry, InflaRx NV's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InflaRx NV's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Debt-to-Revenue falls into.



InflaRx NV Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

InflaRx NV's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.408 + 0.814) / 0.069
=17.71

InflaRx NV's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.408 + 0.814) / 0.008
=152.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


InflaRx NV Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


InflaRx NV (InflaRx NV) Business Description

Traded in Other Exchanges
Address
Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.